EGFR and triple-negative breast carcinoma: Currently, Neratinib is undergoing clinical trials for triple-negative breast cancer (https://clinicaltrials.gov/ct2/show/NCT03812393) and it is under study for HER1-expressing (EGFR) lung adenocarcinoma [25, 26, 36], ovarian carcinoma [28, 37, 38], and biliary tract cancer [39].